Lucid Diagnostics Inc.

Stage 4 · Declining · week 22

As of Oct 22, 2026, Lucid Diagnostics is in Stage 4, the downtrend phase, now in week 22 (since May 21, 2026). It closed at $0.33, 77.7% below its 52-week high and below its 200-day average, which is falling.

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. More about the company

$0.33

+18.16% today

$62.6M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is LUCD early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 27w

S3 14w

S4 22w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 4w → S1 1w → S2 3w → S3 1w → S4 9w → S1 9w → S4 27w → S1 4w → S4 4w → S1 5w → S2 4w → S3 6w → S2 12w → S3 14w → S4 9w → S1 5w → S4 4w → S1 2w → S4 4w → S1 2w → S2 11w → S3 3w → S4 22w current

Total tracked: 165 weeks across 23 stage runs.

LUCD among Medical Devices106th of 141 by relative strength

All 141 →

Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	TXG10x Genomics, Inc.	Stage 2 · wk 48	99	−7.8%
2	RCELAvita Medical, Inc.	Stage 2 · wk 13	98	+40.8%
3	BFLYButterfly Network, Inc. Class A	Stage 2 · wk 26	98	−26.0%
4	HAEHaemonetics Corporation	Stage 2 · wk 17	96	+8.7%
5	GKOSGlaukos Corporation	Stage 2 · wk 25	96	+15.1%
6	AXGNAxogen, Inc.	Stage 3 · wk 2	95	−15.3%
7	NEOGNeogen Corporation	Stage 2 · wk 14	95	−11.7%
8	BVSBioventus Inc. Class A	Stage 2 · wk 15	95	+10.5%
…106	LUCDLucid Diagnostics Inc.	Stage 4 · wk 22	14	−60.9%

vs 52W High

-77.7%

$0.28 lo$1.47 hi

77.7% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 22

1w13w26w

Week 22, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-68.7%

200 DMA: $1.05 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

22.45x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-60.9%

-63.9%

-69.9%

YTD

-70.7%

-72.9%

Scan Membership

Breakout Watch

Latest: 2025-02-14

3 appearances in last 60 days. First seen: 2023-09-21.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 22 · Vol 22.45x

2026-10-21S4

Wk 22 · Vol 2.79x

2026-10-20S4

Wk 21 · Vol 4.48x

2026-10-19S4

Wk 21 · Vol 3.20x

2026-10-16S4

Wk 21 · Vol 1.79x

2026-10-15S4

Wk 21 · Vol 2.32x

2026-10-14S4

Wk 21 · Vol 1.41x

2026-10-13S4

Wk 20 · Vol 0.85x

2026-10-12S4

Wk 20 · Vol 1.28x

2026-10-09S4

Wk 20 · Vol 1.55x

2026-10-08S4

Wk 20 · Vol 2.04x

2026-10-07S4

Wk 20 · Vol 1.41x

Moving averages & range

50 DMA

$0.78

200 DMA

$1.05

52W High

$1.47

52W Low

$0.28

5D Low

$0.28

Resistance levels (recent highs)

20d High

$0.83

60d High

$1.01

120d High

$1.15

250d High

$1.47

Next resistance

+151.8%

to 20d High

ROE

-556.3%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 5.7

Lucid Diagnostics: quick answers

What stage is Lucid Diagnostics in?

As of Oct 22, 2026, Lucid Diagnostics (LUCD) is in Stage 4, the downtrend phase. It entered Stage 4 on May 21, 2026 and is in week 22. What the four stages mean

Is Lucid Diagnostics in an uptrend?

No. Lucid Diagnostics is in a Stage 4 downtrend. It trades 68.7% below its 200-day average, which is falling.

How far is Lucid Diagnostics from its 52-week high?

Lucid Diagnostics closed at $0.33 on Oct 22, 2026, 77.7% below its 52-week high of $1.47. Its 52-week low is $0.28.

How has Lucid Diagnostics performed over the past year?

As of Oct 22, 2026, Lucid Diagnostics is down 72.9% over the past year and down 70.7% so far in 2026.

Which sector and industry is Lucid Diagnostics in?

Lucid Diagnostics is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.